49 results about "Infectious virus" patented technology

The invention relates to the technical field of biological medicine, and discloses a culture medium for human metapneumovirus and application, the culture medium comprises the following components by mass: 850-920 parts of a basic culture medium; the metabolism reprogramming module is prepared from the following components in parts by weight: 0.05 to 0.15 part of 5-methyltetrahydrofolic acid, 0.3 to 0.7 part of N-acetyl-D-mannosamine and 1.0 to 3.0 parts of sodium dichloroacetate; the immune regulation and control module is prepared from 0.005 to 0.015 part of an RIG-I / MAVS pathway inhibitor; the receptor induction module is prepared from 0.5 to 1.5 parts of all-trans retinoic acid; the redox balance module is prepared from the following components in parts by weight: 0.1 to 0.5 part of pegylated superoxide dismutase and 0.002 to 0.008 part of sodium selenite. According to the method, the proportion of infectious virus particles can be remarkably increased, the generation of defective particles is reduced, meanwhile, the production cycle of host cells is prolonged, large-scale continuous culture is supported, and a high-quality and high-efficiency solution is provided for industrial production of gene therapy vectors and virus vaccines.

An implantable or injectable scaffold comprising an antigen, a T memory cell inducer, and other optional components is provided for use in enhancing the immune response to the antigen, in particular for subjects who are elderly, immunosenescent and / or immunocompromised, or undergoing cancer therapy. Coronavirus SARS-CoV-2 has caused millions of confirmed cases and hundreds of thousands of deaths. However, there is no effective drug treatment, and vaccine is in great need to control the spread of such highly infectious virus.

[00121] The present invention relates to a label-free, high throughput method for determining an infectious virus titer in an aqueous sample comprising infectious virus, wherein the method comprises detecting the kinetics of morphological cell alteration, such as cell rounding, following viral infection, determining a parameter defining the curve of the morphological cell alteration as a function of time post infection and determining the infectious virus titer based on a standard curve of the infectious virus at a known infectious titer.

The present invention relates to the technical field of disinfection for medical hyperbaric oxygen chambers. Disclosed is a sterilization and disinfection apparatus for a medical hyperbaric oxygen chamber. According to the present invention, a fixing plate is fixedly connected to a side of a fixing frame close to a fixing mechanism. A mounting plate is fixedly connected to a side of the fixing plate away from the fixing mechanism. Two sides of the mounting plate away from the fixing plate are fixedly connected to two ends of a disinfection lamp, respectively. A disinfection cylinder body is fixed to an air inlet end of an oxygen exhaust pipeline of the hyperbaric oxygen chamber. The disinfection lamp disinfects the gas flowing inside the pipeline, thereby effectively disinfecting and sterilizing the gas exhaled by patients in the hyperbaric oxygen chamber, which is then discharged into the atmosphere outside the chamber through the oxygen exhaust pipeline, avoiding the formation of a new virus source. The apparatus is designed to disinfect dedicated oxygen chambers for individuals infected with infectious viruses, avoiding the formation of a major viral contamination source, and preventing gas containing pathogens exhaled by patients from circulating inside the oxygen exhaust pipeline, thereby avoiding contamination of the pipelines inside the oxygen chamber.

A medical care system having one or more clinician rooms, and one or more patient areas. The clinician rooms and patient areas are separate from one another to prevent an infectious virus (such as COVID-19) from spreading from one room or area to another room or area. A dividing wall is provided between each clinician room and the respective patient area. A glass partition is located in the dividing wall and one or more gloves are provided in the glass partition. Thus, a clinician located in a clinician room can interact with a patient located in the patient area to conduct a physical medical examination, such as for example to take the temperature of the patient or test for a virus.

The invention relates to a nucleic acid detection platform based on an SHERLOCK technology, which is used for diagnosing CAV-2. The SHERLOCK consisting of recombinase polymerase nucleic acid pre-amplification (RPA) and CRISPR-Cas13a is mainly used for specifically recognizing a conserved sequence of CAV-2RNA (Ribonucleic Acid) through crRNA (Complementary Ribonucleic Acid) so as to activate the non-specific'side cutting activity 'of lwCas13a, so that the report RNA is degraded. A real-time fluorescent quantitative PCR (qPCR) system or a lateral flow test strip is used for collecting fluorescent signals generated by cracking of the reporter molecules, and a visual result is displayed. In addition, through HUDSON treatment, RPA-CRISPR can be amplified at room temperature without viral nucleic acid extraction. The detection limit of the method is 1.1 * 10 < 2 > copies / [mu] L, and the method has no cross reaction with other canine infectious viruses. From sample collection to result output, the whole reaction of RPA-CRISPR can be completed within two hours, and the RPA-CRISPR kit is suitable for rapid test of clinical samples and can work well in the field or in primary laboratories. The method can get rid of the limitation of a detection instrument and complex operation, and is suitable for on-site rapid batch detection. The method is preliminarily verified and further optimized and applied.

The present invention relates to a recombinant chimeric antigen targeting poxvirus (particularly monkeypox virus), a subunit vaccine thereof, and its application. The recombinant chimeric antigen of the present invention comprises two immunogens arranged in a specific manner: monkeypox virus A35 protein or its antigenic fragment (or its derivative peptide segment) and monkeypox virus M1 protein or its antigenic fragment (or its derivative peptide segment), which can stimulate immune responses against two infectious virus particles: intracellular mature virus particles (IMV) and extracellular enveloped virus particles (EEV), thereby efficiently stimulating specific immune protection against monkeypox virus. In addition, the poxvirus vaccine of the present invention also has good safety, rapid responsiveness and production capacity support, and has excellent clinical application prospects.

The invention relates to a recombinant chimeric antigen aiming at bovine nodular skin disease virus, an immunogenic composition containing the recombinant chimeric antigen and application of the recombinant chimeric antigen. The bovine nodular skin disease virus recombinant chimeric antigen comprises two immunogens which are connected in series and fused according to a specific sequence: bovine nodular skin disease virus ORF122 and ORF060 proteins or antigenic fragments thereof, and can excite immune response aiming at two infectious virus particles, namely, intracellular mature virus particles (IMV) and cell outer enveloped virus particles (EEV); therefore, the specific immune protection effect on the bovine nodular skin disease virus is efficiently excited; in addition, the bovine nodular skin disease virus vaccine disclosed by the invention also has good safety, quick responsiveness and productivity support, and has an extremely good clinical application prospect.

To provide a sterilizing device which can sufficiently exhibit inactivation effects to highly-infectious viruses which are contained in fluid and flows in a tube, and can exhibit effects for sterilizing all general bacteria.SOLUTION: A fluid sterilizing device has such a structure that a box-shaped body case 1, a sterilizing space 2 in the body case, a mirror plate 3 mounted on an inner wall of the sterilizing space, an inflow side connection part 4, an outflow side connection part 5 are connected to each other by flange connection parts 6 and 7. A blade driving part 8 is mounted between the inflow side connection part 4 and the body case 1, a high-performance filter 9 in an attitude perpendicular to a flow channel is mounted between the outflow side connection part in the body case, and a flow straightening member 10 is mounted on the downstream side of the blade driving part 8. A deep ultraviolet LED 11 is mounted on the inclined surface outside the body case 1 so as to be capable of being emitted from the window of an opening to inside.SELECTED DRAWING: Figure 1

The invention belongs to the technical field of medical instruments, and discloses a medical pre-disinfection whole-course protective glove and a preparation method thereof.The body of the medical pre-disinfection whole-course protective glove is prepared from a latex outer layer and a medicine-soaked gauze lining layer which are integrally formed; the medicine-soaked gauze lining layer is prepared by soaking medical gauze in ethanol-herbal slow-release disinfection gel and then drying; the ethyl alcohol-herbal slow-release disinfection gel has weak viscosity, and when the ethyl alcohol-herbal slow-release disinfection gel is not used, the upper face and the lower face of the interior of the latex glove body are bonded, air in the latex glove body is emptied, meanwhile, an opening of the latex glove body is closed, and active ingredients are prevented from volatilizing and escaping. According to the invention, extra hand disinfection is not needed, active protection can be provided in the whole process of use by medical personnel, the protection effect is good, the use is convenient, the cost performance is high, and the device can be widely applied to the scenes of high-risk infectious virus sampling, field emergency medical assistance, chemotherapy drug configuration and the like, and has a wide application range.

The invention discloses respiratory tract infectious virus prevention and treatment equipment which comprises an oral cavity part, a throat part and a chest part, the oral cavity part comprises a spherical infrared radiation shell, an electric heating layer is attached to the inner layer of the spherical infrared radiation shell, and a holding tube communicated with the interior of a spherical cavity is fixedly installed at the lower end of the spherical infrared radiation shell; the present invention provides a device for preventing and treating new coronal influenza, influenza A, pandemic influenza and recently found respiratory infectious viruses such as HMPV.

The present invention aims to provide a method for testing the function of antibodies that uses safe antigens and gives results more quickly. The present invention relates to a method for determining antibody-dependent enhancement ability of antibodies, including contacting, in the presence of a test antibody, Fcγ receptor-expressing cell with single round infectious virus particles containing a gene with a region encoding a labeled protein and a region encoding non-structural (NS) proteins 1 to 5 of the yellow fever virus genome, a capsid protein of a virus, and an outer shell protein (Envelope) of a virus, wherein when the measured label is greater than that of a negative control cell, the test antibody is determined to have an antibody-dependent enhancement ability, and the like.

Engineered, replication-deficient influenza viruses that are infectious and stimulate broadly-cross protective immunity against multiple different influenza strains have been developed. Compositions and methods for providing protective immune responses against influenza are provided. The methods deliver compositions of intact, replication-deficient influenza viruses by intradermal administration in an amount effective to elicit or stimulate a cross-protective immune response to influenza viruses in the recipient following a single administration. Because the engineered influenza viruses are non-replicating, they are safe and effective in immunocompromised subjects. Methods for delivering co-stimulatory molecules, growth factors, adjuvants and / or cytokines together with the non-replicating influenza viruses are also provided.

Provided are innovative compositions for tethering blocking an inactivating of airborne respiratory infectious viruses. The compositions comprise bispecific proteins with two different antigen binding regions (ABR), which are typically configured as immunoglobulin “single variable domains” (ISV). A first ISV binds to a surface protein found on an airborne infectious virus. A second ISV binds to a mucin protein, e.g. a mucin protein present on ocular, nasopharyngeal, tracheal and / or oral surfaces of a mammal. The two ISV are joined by a polypeptide linker.

Described herein are processes for purifying infectious virus particles and uses of protamine in such processes.

Disclosed herein are synthetic VP1 proteins that contain engineered disulfide bonds. In some embodiments, the synthetic VP1 proteins with engineered disulfide bonds self-assemble into non-infectious virus-like particles (VLPs) that are more stable that non-infectious VLPs that resulted from self-assembly of VP1 proteins that lack engineered disulfide bonds.

The present invention discloses an automatic diagnosis system for infectious viruses and a diagnosis method thereof, which belongs to the technical field of medical devices. It includes a seat, a workbench, a control terminal, a mobile terminal and a cloud server; the seat is placed on the ground, and a receiving groove is provided on the top of the seat, and a plurality of rollers are arranged side by side in the receiving groove, and the two ends of each roller are respectively connected to the inner wall of the receiving groove for rotation; an automatic replacement isolation film device includes an isolation film, a first shell, a first capstan, a first capstan motor, a second shell, a second capstan and a second capstan motor, and the first shell and the second shell are respectively located on opposite sides of the seat along the roller arrangement direction, and the axial direction of the first capstan, the axial direction of the second capstan are the same as the axial direction of the roller, and a first opening is provided on the top of the first shell. The diagnosis efficiency of the present invention is high, and it can prevent mutual infection between patients and medical staff during consultation.

The utility model relates to the technical field of medical instruments, in particular to a sickbed isolation device. The device comprises four groups of supporting mechanisms, isolating mechanisms and four groups of connecting mechanisms, the isolation mechanism comprises an isolation cover body covering the outer side of the sickbed, an isolation curtain fixedly arranged on one side in the isolation cover body so as to divide the isolation cover body into a first space and a second space, and an air filtering assembly arranged in the first space; the first fixing assembly is arranged between the ground and the isolation cover body in a sealed mode and used for fixing the isolation cover body, and the second fixing assembly is arranged between the ground and the isolation curtain in a sealed mode and used for fixing the isolation curtain. The device solves the problem that infectious viruses can be diffused to the outside air when medical staff enter and exit from the isolation assembly.

The invention relates to a recombinant chimeric antigen aiming at bovine nodular skin disease virus as well as a preparation method and application of the recombinant chimeric antigen. The bovine nodular skin disease virus recombinant chimeric antigen comprises four immunogens which are connected in series and fused according to a specific sequence: bovine nodular skin disease virus ORF122, ORF060, ORF074 and ORF117 proteins or antigenic fragments thereof, and can excite immune response aiming at two infectious virus particles, namely, intracellular mature virus particles (IMV) and extracellular membrane virus particles (EEV); therefore, the specific immune protection effect on the bovine nodular skin disease virus is efficiently excited; in addition, the bovine nodular skin disease virus vaccine disclosed by the invention also has good safety, quick responsiveness and productivity support, and has an extremely good clinical application prospect.

The application provides an avian leukosis virus multi-subtype antigen epitope fusion protein, a multi-subtype recognition antibody, a detection kit and application thereof. The amino acid sequence of the avian leukosis virus multi-subtype antigen epitope fusion protein is shown as SEQ ID NO:1. Experiments show that the avian leukosis virus multi-subtype antigen epitope fusion protein is reactive to avian leukosis virus multi-subtype serum and is not reactive to other common chicken infectious virus or bacterial serum. The avian leukosis virus multi-subtype antigen epitope fusion protein can be used for preparing multi-subtype recognition antibodies by immunizing animals. The multi-subtype recognition antibody can be specifically recognized with multi-subgroup avian leukosis specific antigen epitopes, a detection kit is developed, and the detection kit is used for rapid screening and purification of chicken population avian leukosis virus, and has a good application prospect.

The application provides application of tanshinone or a derivative thereof in preparation of a monkeypox virus resisting drug. In a cell model infected by the monkeypox virus, production of infectious virus particles can be significantly reduced. In a mouse infection model, Tanshinone VII can effectively reduce pathological damage of lung tissues and improve survival rate of animals. The above evidence indicates that Tanshinone VII has potential efficacy in resisting the monkeypox virus. It is inferred that tanshinone or the derivative thereof can play a double role in resisting the monkeypox virus and host protection.

The invention relates to the technical field of air sterilization and purification, and discloses an aerosol-infected virus decomposition device which comprises a base, an outer frame is fixedly connected to the top of the base, a top cover is fixedly connected to the inner wall of the end, away from the base, of the outer frame, and an air suction pump is fixedly connected to the end face of the side, close to the top cover, of the base. An air inlet pipe is fixedly connected to the inner wall of the end face of the side, close to the air suction pump, of the top cover, a motor is fixedly connected to the inner wall of the side, close to the outer frame, of the base, and a control panel is arranged on the inner wall of the side, close to the air suction pump, of the base. When the device is used and the device is placed in a space where aerosol heat transfer viruses need to be killed, the air suction pump in the water removal component is started, air needing to be killed starts to be absorbed in a guiding mode and enters the device, meanwhile, the motor is started to drive the output rod to operate, the output rod can drive the output belt to conduct transmission, and the device is driven by the motor to rotate. When the output belt is in transmission, the transmission rod on the inner wall of the other side is driven to start to rotate and operate.

Disclosed herein are engineered cell lines that contain a modification in the ISG15 gene, where the modification in the ISG15 gene increases total viral particle production and / or infectious viral particle production compared to a control cell line that is identical to the engineered cell line except for the modification in the ISG15 gene. Also disclosed herein are methods for increasing viral particle production and methods for identifying genes to delete in a cell or cell line.

A chromatography medium comprising porous beads having an inner porous core and an outer porous shell is used for chromatographic separation of enveloped or membranous biological particles from impurities such as contaminant DNA and / or protein. The core is capable of binding molecules via hydrophobic interactions; however, the pore size of the shell does not allow particles having a size of 20 nm and larger to permeate into the bead and interact with the core. The separation is performed at a pH of less than 7.4. The enveloped or membranous biological particles may have been subjected to a prior chromatographic capture step. When used for purification of enveloped virus particles the inventive process was found to yield a remarkably high rate of infectious virus particles.

The present invention provides compositions, vaccines, and methods for inducing protective immunity to immunogens in humans. Protective immune responses are obtained by using saRNA, particularly VRP vectors as a prime and MVA vectors for boosting. Specifically, the present invention relates to genetically engineered (recombinant) VRP and MVA vectors that contain at least one heterologous nucleotide sequence encoding an antigenic determinant of an infectious virus (e.g., EBV).

The present invention relates to a label-free, high throughput method for determining the titer of an infectious virus in an aqueous sample comprising the infectious virus wherein the method comprises detecting the kinetics of morphological cell alterations, such as cell rounding, following virus infection, determining parameters defining a curve of morphological cell changes as a function of post-infection time, and determining the infectious virus titer based on a standard curve of the infectious virus at a known infection titer.

The present invention discloses an automatic dosing adjustment and sufficient flow-pushing device based on the AAO process, which belongs to the field of sewage treatment technology. It includes a sewage pretreatment tank and a biochemical tank, and the biochemical tank is sequentially divided into a disinfection tank, an anaerobic tank, an anoxic tank, and an aerobic tank; a water outlet is fixedly connected between the bottom of the disinfection tank and the anaerobic tank, the sewage pretreatment tank is fixedly connected to the biochemical tank, the right side of the aerobic tank is fixedly connected to a sewage pipe, the right end of the sewage pipe is fixedly connected to a sedimentation tank, a mud discharge pipe is provided at the bottom of the sedimentation tank, and a drain pipe is fixedly connected to the right side of the sedimentation tank; this improved AAO sewage treatment system realizes the linkage between the amount of drug added and the water level of the disinfection tank through a clever structural design. When the water level of the disinfection tank changes, the floating plate drives the top plate to act on the perforated rotating plate, thereby controlling the amount of drug outflow from the drug storage chamber. This design overcomes the defects of extensive operation in the field of urban sewage treatment, avoids the waste of drug consumption and energy consumption, and at the same time, can effectively guarantee the amount of disinfectant added, ensure the effective elimination of bacteria and viruses, and reduce the risk of transmission of infectious viruses.

Chromatographic media comprising porous beads having an inner porous core and an outer porous shell for the chromatographic separation of enveloped or membrane-like biological particles from impurities such as contaminant DNA and / or proteins. The core is capable of binding molecules by hydrophobic interaction, however, the pore size of the shell does not allow particles having a size of 20 nm and greater to penetrate into the beads and interact with the core. The separation is carried out at a pH of less than 7.4. The coated or film-like bio-particles may be subjected to a pre-chromatographic capture step. When used to purify enveloped viral particles, the method of the invention was found to produce very high ratios of infectious viral particles.

The present invention relates to modular systems for vaccination against infectious agents that involves the delivery of, e.g., exosome-loaded, antigen-encoding mRNAs to and into cells and tissues of the immunized subject. The present invention also relates to compositions and methods for the design, preparation, manufacture, formulation, and / or use of vaccines, e.g., nucleic acid vaccines, loaded into extracellular vesicles, e.g., exosomes loaded with synthetic mRNAs encoding multiple surface and cytoplasmic antigens of interest, e.g., antigenic polypeptides derived from an infectious virus, e.g., SARS-CoV-2, designed to elicit strong humoral and cellular immune responses due to the simultaneous expression of antigens in their native state and as exosome-associated antigens.

An improved method of deoptimization of nucleic acids, particularly nucleic acids associated with genes and / or open reading frames (ORFs) of a variety of pathogens including viruses, retroviruses, bacteria, fungi, and the like. Nucleic acids may be related to genes and / or ORFs from infectious viruses or other diseases and be associated with the elicitation of a protective response when inserted, using recombinant techniques, into a vector and used in a vaccine composition. The nucleic acid sequence of one or more ORFs may be optimized or deoptimized for use in an improved recombinant vaccine to elicit an immune response against an infectious agent when administered to a subject using a variety of dosing and timing regimens.